Trinity Biotech PLC (TRIB) stock
Close on Nov 12, 2026Market cap $110.02MP/E –Yield –
Trinity Biotech PLC saw revenue fall 28.9% to $43.79M over fiscal 2025. Free cash flow was -$6.02M. At the latest close the market valued the company at $110.02M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- $110.02M
- P/E ratio
- –
- Price to sales
- 2.51
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -5.47%
Fundamentals
- Revenue
- $43.79M
- Net income
- -$37.38M
- Free cash flow
- -$6.02M
Trading
- Previous close
- $5.82
- Open
- $5.98
- Day's range
- $5.63 – $6.08
- Volume
- 10,053
- Average volume (20 days)
- 11,849
- Beta (5 years)
- 1.43
- 52-week range
- $5.00 – $52.51
- RSI (14 days)
- 40.5
- Volatility (1 year)
- 114.4%
- Relative volume
- 0.52×
- WACC
- 12.0%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | TRIB | S&P 500 | Difference | TRIB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.4% | -2.7% | −7.7 pts | ||
| 3 months | -49.5% | -1.7% | −47.8 pts | ||
| Year to date | -75.2% | +11.9% | −87.1 pts | ||
| 1 year | -78.2% | +12.0% | −90.2 pts | ||
| 3 years | -90.7% | +78.2% | −168.9 pts | -54.7% | +21.2% |
| 5 years | -98.0% | +73.2% | −171.3 pts | -54.4% | +11.6% |
| 10 years | -99.4% | +309.6% | −409.1 pts | -40.3% | +15.1% |
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
Gross profit
Operating income
Net income
Free cash flow
Press releases
Releases Trinity Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Trinity Biotech
In Vitro & In Vivo Diagnostic Substances
Trinity Biotech operates in the healthcare diagnostics industry, focusing on research, development, and manufacturing of medical diagnostic solutions. The company conducts its operations across three primary business segments: Clinical Laboratory, Laboratory Services, and Point of Care. Its offerings and developmental projects include continuous glucose monitoring testing devices and Premier instruments, alongside clinical testing capabilities. The organization serves a global customer base comprising healthcare clients and laboratory purchasers located across the Americas, Europe, Asia, and Africa.
Company profile, executives and historyTrinity Biotech stock: common questions
What is Trinity Biotech's stock price?
TRIB closed at $5.88 on Nov 12, 2026, up 1.03% on the day. Over the past 52 weeks it traded between $5.00 and $52.51.
What is Trinity Biotech's market cap?
Trinity Biotech was worth $110.02M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
How much revenue does Trinity Biotech make?
Trinity Biotech reported revenue of $43.79M for fiscal 2025, down 28.9% from a year earlier.
Does Trinity Biotech pay a dividend?
No. Trinity Biotech has not paid a cash dividend over the last twelve months.
How has TRIB stock performed over the past year?
Including dividends, TRIB returned -78.2% over the past year, against +12.0% for the S&P 500.
Who are Trinity Biotech's competitors?
Companies most similar to Trinity Biotech by business, industry and size include TKNO, ICCC, NNNN, NTLA, JAGX.
See a number that looks wrong?